Evidence map›Paper›PMID 39330594›Full record

ArticleToxics2024

Increasing Accessibility of Bayesian Network-Based Defined Approaches for Skin Sensitisation Potency Assessment.

Tomaz Mohoric, Anke Wilm, Stefan Onken, Andrii Milovich, Artem Logavoch, Pascal Ankli, Ghada Tagorti, Johannes Kirchmair, Andreas Schepky, Jochen Kühnl and 3 more

Abstract read
In one paragraph

Article in Toxics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tomaz MohoricEdelweiss Connect GmbH, Hochbergerstrasse 60C, 4057 Basel, Switzerland.
Anke WilmBeiersdorf AG, Beiersdorfstraße 1-9, 22529 Hamburg, Germany.
Stefan OnkenBeiersdorf AG, Beiersdorfstraße 1-9, 22529 Hamburg, Germany.
Andrii MilovichEdelweiss Connect GmbH, Hochbergerstrasse 60C, 4057 Basel, Switzerland.
Artem LogavochEdelweiss Connect GmbH, Hochbergerstrasse 60C, 4057 Basel, Switzerland.
Pascal AnkliEdelweiss Connect GmbH, Hochbergerstrasse 60C, 4057 Basel, Switzerland.
Ghada TagortiEdelweiss Connect GmbH, Hochbergerstrasse 60C, 4057 Basel, Switzerland.
Johannes KirchmairDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.ORCID 0000-0003-2667-5877
Andreas SchepkyBeiersdorf AG, Beiersdorfstraße 1-9, 22529 Hamburg, Germany.ORCID 0000-0001-5258-3605
Jochen KühnlBeiersdorf AG, Beiersdorfstraße 1-9, 22529 Hamburg, Germany.ORCID 0000-0001-8421-9381
Abdulkarim NajjarBeiersdorf AG, Beiersdorfstraße 1-9, 22529 Hamburg, Germany.ORCID 0000-0003-4620-9830
Barry HardyEdelweiss Connect GmbH, Hochbergerstrasse 60C, 4057 Basel, Switzerland.
Johanna EbmeyerBeiersdorf AG, Beiersdorfstraße 1-9, 22529 Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin sensitisation is a critical adverse effect assessed to ensure the safety of compounds and materials exposed to the skin. Alongside the development of new approach methodologies (NAMs), defined approaches (DAs) have been established to promote skin sensitisation potency assessment by adopting and integrating standardised in vitro, in chemico, and in silico methods with specified data analysis procedures to achieve reliable and reproducible predictions. The incorporation of additional NAMs could help increase accessibility and flexibility. Using superior algorithms may help improve the accuracy of hazard and potency assessment and build confidence in the results. Here, we introduce two new DA models, with the aim to build DAs on freely available software and the newly developed kDPRA for covalent binding of a chemical to skin peptides and proteins. The new DA models are built on an existing Bayesian network (BN) modelling approach and expand on it. The new DA models include kDPRA data as one of the in vitro parameters and utilise in silico inputs from open-source QSAR models. Both approaches perform at least on par with the existing BN DA and show 63% and 68% accuracy when predicting four LLNA potency classes, respectively. We demonstrate the value of the Bayesian network's confidence indications for predictions, as they provide a measure for differentiating between highly accurate and reliable predictions (accuracies up to 87%) in contrast to low-reliability predictions associated with inaccurate predictions.

Indexed as

Bayesian networkdefined approachesNAMsnext-generation risk assessmentskin sensitisation

Identifiers

PMID39330594
PMCPMC11435505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.